Research programme: TNF pathway modulators - RigelAlternative Names: TNF pathway modulators research programme - Rigel
Latest Information Update: 11 Nov 2005
At a glance
- Originator Rigel Pharmaceuticals
- Mechanism of Action Tumour necrosis factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 10 Nov 2005 No development reported - Preclinical for Inflammation in USA (unspecified route)
- 10 Apr 2000 New profile
- 10 Apr 2000 Preclinical development for Inflammation in USA (Unknown route)